...
首页> 外文期刊>Clinical and experimental pharmacology & physiology >N(G)-nitro-L-arginine methyl ester potentiates anaphylactic venoconstriction in rat perfused livers.
【24h】

N(G)-nitro-L-arginine methyl ester potentiates anaphylactic venoconstriction in rat perfused livers.

机译:N(G)-硝基-L-精氨酸甲酯增强大鼠灌注肝脏中的过敏性静脉收缩。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

1. The effects of the nitric oxide (NO) synthase inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) on anaphylaxis-induced venoconstriction were examined in rat isolated livers perfused with blood-free solutions in order to clarify the role of NO in anaphylactic venoconstriction. 2. Rats were sensitized with ovalbumin (1 mg) and, 2 weeks later, livers were excised and perfused portally in a recirculating manner at a constant flow with Krebs'-Henseleit solution. The antigen (ovalbumin; 0.1 mg) was injected into the reservoir 10 min after pretreatment with L-NAME (100 micromol/L) or D-NAME (100 micromol/L) and changes in portal vein pressure (Ppv), hepatic vein pressure (Phv) and perfusate flow were monitored. In addition, concentrations of the stable metabolites of NO ( and ) were determined in the perfusate using an HPLC-Griess system. 3. The antigen caused hepatic venoconstriction, as evidenced by an increase in Ppv from a mean (SEM) baseline value of 7.7 +/- 0.1 cmH2O to a peak of 21.4 +/- 1.1 cmH2O at 3 min in D-NAME-pretreated livers. Pretreatment with L-NAME augmented anaphylactic venoconstriction, as reflected by a higher Ppv (27.4 +/- 0.8 cmH2O) after antigen than observed following D-NAME pretreatment. The addition of L-arginine, a precursor for the synthesis of NO, reversed the augmentation of anaphylactic venoconstricion by L-NAME. This suggests that hepatic anaphylaxis increased the production of NO, which consequently attenuated anaphylactic venoconstriction. However, perfusate NOx levels did not increase significantly after antigen in livers pretreated with either L-NAME or D-NAME. 4. In conclusion, L-NAME potentiates rat anaphylactic hepatic venoconstriction, suggesting that NO contributes to the attenuation of the venoconstriction. However, this functional evidence was not accompanied by corresponding changes in perfusate NOx concentrations.
机译:1.在灌注了无血溶液的大鼠离体肝脏中,研究了一氧化氮(NO)合酶抑制剂N(G)-硝基-L-精氨酸甲酯(L-NAME)对过敏性诱发的静脉收缩的影响。阐明NO在过敏性静脉收缩中的作用。 2.用卵白蛋白(1mg)致敏大鼠,并且2周后,切除肝脏,并以恒定流量用Krebs'-Henseleit溶液以循环方式门静脉灌注。在用L-NAME(100 micromol / L)或D-NAME(100 micromol / L)预处理并在门静脉压力(Ppv),肝静脉压力发生变化后的10分钟后,将抗原(卵清蛋白; 0.1 mg)注射到储库中(Phv)和灌注液流量被监控。此外,使用HPLC-Griess系统测定灌注液中NO(和)的稳定代谢产物的浓度。 3.抗原引起肝静脉收缩,在P-v从D-NAME预处理的肝脏在3分钟时的平均(SEM)基线值从7.7 +/- 0.1 cmH2O的峰值增加到21.4 +/- 1.1 cmH2O的峰值即可证明。用L-NAME进行预处理可增加过敏性静脉收缩,反映在抗原后的Ppv(27.4 +/- 0.8 cmH2O)比D-NAME进行预处理后观察到的要高。 L-精氨酸(NO合成的前体)的添加逆转了L-NAME对过敏性静脉收缩的增强作用。这表明肝脏过敏反应增加了NO的产生,因此减弱了过敏性静脉收缩。但是,在用L-NAME或D-NAME预处理的肝脏中进行抗原治疗后,灌注液中的NOx水平并未显着增加。 4.总之,L-NAME增强大鼠过敏性肝静脉收缩,提示NO有助于静脉收缩的减弱。但是,该功能证据并未伴随灌注液NOx浓度的相应变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号